Cancer remains a predominant global health concern, necessitating effective treatment options. Conventional cancer therapies, particularly chemotherapy, often face constraints such as low selectivity, insufficient solubility, and multidrug resistance (MDR), which diminish effectiveness and exacerbate negative effects. Metal oxide nanoparticles (MONPs), such as iron oxide, zinc oxide, and copper oxide, offer a promising solution by enhancing targeted drug delivery, reducing systemic toxicity, and mitigating chemotherapy-induced disabilities like neurotoxicity and cardiotoxicity. Nanocarriers conjugated with drugs can improve drug delivery within the body and enhance their circulation in the bloodstream. Recent advancements in MONP synthesis and functionalization have further improved their stability and drug-loading capacity, making them a valuable tool in cancer treatment. MONPs have distinctive physicochemical characteristics, enabling better imaging, drug encapsulation, and targeted medication delivery to cancerous cells. These nanocarriers enhance treatment effectiveness through focused and controlled drug release, reducing off-target effects and addressing drug resistance. This review aims to explore the potential of MONPs as efficient nanocarriers for anticancer drugs, addressing limitations of traditional chemotherapy such as poor specificity, systemic toxicity, and drug resistance. Additionally, the review discusses recent advancements in MONP synthesis and functionalization, which enhance their stability, drug-loading capacity, and compatibility.
癌症仍是全球主要的健康问题,亟需有效的治疗手段。传统癌症疗法,尤其是化疗,常面临选择性低、溶解度不足及多药耐药性等限制,这些因素不仅降低疗效,还加剧了不良反应。金属氧化物纳米颗粒(如氧化铁、氧化锌和氧化铜)通过增强靶向药物递送、降低全身毒性并减轻化疗引起的神经毒性和心脏毒性等副作用,为癌症治疗提供了前景广阔的解决方案。与药物结合的纳米载体能够改善药物在体内的递送效率,并延长其在血液循环中的停留时间。近期在金属氧化物纳米颗粒合成与功能化方面的进展进一步提升了其稳定性和载药能力,使其成为癌症治疗中的重要工具。金属氧化物纳米颗粒具有独特的物理化学特性,能够实现更优的成像效果、药物包封及针对癌细胞的靶向给药。这些纳米载体通过聚焦可控的药物释放机制提高治疗效果,减少脱靶效应并克服耐药性问题。本文旨在探讨金属氧化物纳米颗粒作为抗癌药物高效纳米载体的潜力,以应对传统化疗中存在的特异性差、全身毒性和耐药性等局限。此外,本文还综述了金属氧化物纳米颗粒合成与功能化的最新进展,这些进展显著提升了其稳定性、载药能力及生物相容性。